08:31 AM EDT, 04/22/2024 (MT Newswires) -- Pfizer ( PFE ) said Monday that the European Commission has granted marketing authorization for Emblaveo to treat adults with multidrug-resistant infections.

Emblaveo was approved to treat complicated intra-abdominal infections, hospital-acquired pneumonia including ventilator-associated pneumonia, and complicated urinary tract infections including pyelonephritis, according to Pfizer ( PFE ). It is also indicated to treat infections due to aerobic Gram-negative organisms in adult patients with limited treatment options, the company added.

The marketing authorization, which is valid in all 27 EU member states as well as in Iceland, Liechtenstein, and Norway, was based on the results from a phase 3 program evaluating the efficacy, safety, and tolerability of Emblaveo, Pfizer ( PFE ) said.